C57BL/6-Slc34a1em1Cawa/Orl

Status

Available to order

EMMA IDEM:13238
Citation informationRRID:IMSR_EM:13238 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

International strain nameC57BL/6-Slc34a1em1Cawa/Orl
Alternative nameC57Bl/6-Slc34a1 em2Cgen
Strain typeEndonuclease-mediated
Allele/Transgene symbolSlc34a1em1Cawa
Gene/Transgene symbolSlc34a1

Information from provider

ProviderCarsten A Wagner
Provider affiliationPhysiology, University Zurich
Additional ownerDr. Carsten A Wagner Institute of Physiology University Zurich Winterthurerstrasse 190 8057-Zurich Switzerland
Genetic informationThe Slc34a1 gene encoding the sodium/phosphate cotransporter NaPi-IIa was mutated by CRISPR/Cas-mediated genome engineering in order to truncate amino acids 91-97.
Phenotypic informationHomozygous:
Homozygous Slc34a1-em2Cgen mice are indistinguishable from wild-type with regard to several parameters related to phosphate homeostasis, both under standard and low phosphate diet (Bieri et al.; PubMed ID: 35414099). Mutations of the SLC34A1 gene in humans are one of the causes of idiopathic infantile hypercalcemia (IIH; OMIM: 616963), and the 91del7 truncation has been suggested to be among the pathogenic mutations. Although mice with the 91del7 truncation do not phenocopy the human IIH alterations, they may help to clarify the role of this mutation in phosphate homeostasis.

Heterozygous:
Heterozygous Slc34a1-em2Cgen mice are indistinguishable from wild-type with regard to several parameters related to phosphate homeostasis, both under standard and low phosphate diet (Bieri et al.; PubMed ID: 35414099).
Breeding historyHeterozygous and homozygous mice breed without problems.
References
  • The human pathogenic 91del7 mutation in SLC34A1 has no effect in mineral homeostasis in mice.;Bieri Cornelia, Daryadel Arezoo, Bettoni Carla, Pastor-Arroyo Eva-Maria, Schnitzbauer Udo, Hernando Nati, Wagner Carsten A, ;2022;Scientific reports;12;6102; 35414099
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreCNRS-TAAM – Typing and Archiving of Animal Models, Orléans, France
Animals used for archivinghomozygous C57BL/6 males

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

Literature references

  • The human pathogenic 91del7 mutation in SLC34A1 has no effect in mineral homeostasis in mice.;Bieri Cornelia, Daryadel Arezoo, Bettoni Carla, Pastor-Arroyo Eva-Maria, Schnitzbauer Udo, Hernando Nati, Wagner Carsten A, ;2022;Scientific reports;12;6102; 35414099

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable), as well as a CRISPR surcharge.

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.​
Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).